Breakthrough Long-acting Prevention Solution Launched: The U.S. Food and Drug Administration (FDA) has officially approved Bravecto® Quantum (fluralaner extended-release injectable suspension) developed by Merck Animal Health.

This innovative drug enables a single injection to provide dogs with up to 12 months of continuous protection, effectively treating and controlling infestations of Asian longhorned tick and Gulf Coast tick. Addressing the Risk of Tick-Borne Disease Transmission Asian longhorned tick and Gulf Coast tick are important vectors for various zoonotic pathogens, and their distribution has been expanding in recent years. The newly approved sustained-release injection utilizes breakthrough formulation technology, allowing the active ingredient fluralaner to maintain stable blood concentrations in animals throughout the year, effectively blocking the transmission of diseases by ticks from the source. Compared to traditional topical spot-on or oral tablets that require monthly administration, this solution significantly reduces the medication management burden for pet owners. Technological Upgrade in the Animal Health Market The approval by Merck Animal Health marks a significant advancement in the long-acting antiparasitic drug technology pathway. Against the backdrop of rising pet medical expenditures, antiparasitic products with longer-lasting and more convenient features are expected to accelerate the replacement of existing market products. Industry analysts point out that this product will further strengthen Merck’s technological leadership in the field of pet parasite prevention and control, and bring new growth momentum to the company’s animal health business. Regulatory Approval and Market Access According to FDA disclosure, the drug demonstrated excellent safety characteristics and control efficacy in clinical trials. With the qualification for entry into the US market, Merck Animal Health will gradually advance registration applications in major global markets. Analysts expect that the product is likely to complete the approval process in the EU and other relevant markets within 2024.